US 12240846
5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases
granted A61KA61K31/437A61K31/444
Quick answer
US patent 12240846 (5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases) held by Enliven Inc. expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Enliven Inc.
- Grant date
- Tue Mar 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 14
- CPC classes
- A61K, A61K31/437, A61K31/444, A61K31/496, A61K31/4995